Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$41.3 million.

  • Allogene Therapeutics' Consolidated Net Income rose 3659.72% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 2365.49%. This contributed to the annual value of -$257.6 million for FY2024, which is 2129.01% up from last year.
  • Per Allogene Therapeutics' latest filing, its Consolidated Net Income stood at -$41.3 million for Q3 2025, which was up 3659.72% from -$50.9 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Consolidated Net Income peaked at $1.9 million during Q4 2021, and registered a low of -$97.0 million during Q1 2023.
  • Moreover, its 5-year median value for Consolidated Net Income was -$66.4 million (2024), whereas its average is -$64.5 million.
  • In the last 5 years, Allogene Therapeutics' Consolidated Net Income soared by 10276.07% in 2021 and then plummeted by 504653.99% in 2022.
  • Allogene Therapeutics' Consolidated Net Income (Quarter) stood at $1.9 million in 2021, then tumbled by 5046.54% to -$93.6 million in 2022, then increased by 15.8% to -$78.8 million in 2023, then increased by 27.02% to -$57.5 million in 2024, then grew by 28.2% to -$41.3 million in 2025.
  • Its Consolidated Net Income was -$41.3 million in Q3 2025, compared to -$50.9 million in Q2 2025 and -$59.8 million in Q1 2025.